Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Malignant melanoma (including melanoma of unknown primary site, recurrent and pretreated systemic melanoma and/or melanoma with parenchymal CNS metastases) with leptomeningeal metastasis as demonstrated by a positive CSF (cerebrospinal liquor) cytology AND/OR by the presence of characteristic signs and symptoms of leptomeningeal metastasis supported by an MRI scan indicating the presence of meningeal tumour~* CSF flow abnormalities must be excluded~* Males or females ≥ 18 years of age~* Karnofsky Performance Status \> 50%~* Adequate organ function (adequate bone marrow reserve, adequate liver function, adequate renal function. adequate blood clotting)~Exclusion Criteria:~* Unresected parenchymal brain metastases with a diameter \> 3 cm~* Prior non melanoma malignancy (unless adequately treated carcinoma in situ of the cervix or non melanoma skin cancer)~* Prior intrathecal chemotherapy~* Prior treatment with systemic cytarabine or nitrosureas~* The patient ist pregnant or breast feeding~* Severe, active co-morbidities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).